Avaxia Biologics, Inc. Reports That Lead Product AVX-470 Achieves Objectives In Phase 1b Clinical Trial In Ulcerative Colitis
5/2/2014 11:50:25 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that primary and secondary objectives were successfully met in a first-in-human Phase 1b clinical trial of AVX-470, an oral anti-TNF bovine polyclonal antibody, in patients with active ulcerative colitis. he primary objective of the trial was to evaluate the safety and tolerability of AVX-470. No treatment-related serious adverse events (SAEs) were observed, and there were no allergic reactions or opportunistic infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by